Comparative Pharmacology
Head-to-head clinical analysis: RIMANTADINE HYDROCHLORIDE versus VISTIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RIMANTADINE HYDROCHLORIDE versus VISTIDE.
RIMANTADINE HYDROCHLORIDE vs VISTIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Rimantadine is a tricyclic amine antiviral that inhibits influenza A virus replication by blocking the M2 proton ion channel, preventing viral uncoating and release of viral RNA into host cells.
Cidofovir is a nucleotide analogue that inhibits viral DNA polymerase by incorporating into viral DNA and causing chain termination, with selectivity for cytomegalovirus (CMV) DNA polymerase.
100 mg orally twice daily for 7 days; initiate within 48 hours of symptom onset.
5 mg/kg intravenously once weekly for 2 consecutive weeks, then every other week thereafter.
None Documented
None Documented
25.4 hours (range 13–65 h); prolonged in elderly (38 h) and severe renal impairment (CrCl <10 mL/min: up to 130 h).
Terminal elimination half-life is approximately 1.5-2 hours in patients with normal renal function. In patients with renal impairment, the half-life can extend to 5-10 hours or longer, necessitating dose adjustment based on creatinine clearance.
Renal: 75% unchanged; fecal: <10%; biliary: minimal. Total clearance 2.5 mL/min/kg.
Primarily renal excretion via glomerular filtration and active tubular secretion. Approximately 90-95% of the dose is excreted unchanged in the urine within 24 hours. Biliary/fecal excretion accounts for <5%.
Category A/B
Category C
Antiviral
Antiviral